Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

7 Notable AI Companies in Clinical Research to Watch in 2021

   3817
7 Notable AI Companies in Clinical Research to Watch in 2021

The clinical trial is a critical stage of drug development workflow, with an estimated average success rate of about 11% for drug candidates moving from Phase 1 towards approval. Even if the drug candidate is safe and efficacious, clinical trials might fail due to the lack of financing, insufficient enrollment or poor study design. [Fogel DB. 2018].  

Artificial Intelligence (AI) is increasingly perceived as a source of opportunities to improve operational efficiency of clinical trials, and minimize clinical development costs.  Typically AI vendors offer their services and expertises in the three main areas. AI start-ups in the first area help to unlock information from disparate data sources, such as scientific papers, medical records, disease registries, and even medical claims by applying Natural Language Processing (NLP). This can support patient recruitment and stratification, site selection, improve clinical study design and understanding of diseases mechanisms. As an example, about 18 % of clinical studies fail due to insufficient recruitment, as 2015 study reported.

Are We At The Beginning Of Stem Cell Revolution?

   441
Are We At The Beginning Of Stem Cell Revolution?

A decade ago, iPSC (induced Pluripotent Stem Cell) technology was viewed as science fiction. iPSC can be obtained from adult tissues by applying a set of molecules - transcriptional factors - that can reprogram cells' fate back. This Nobel Prize-winning technology opens a landscape of opportunities, as in contrast to embryonic stem cells, iPSCs production is not complicated by a number of ethical issues as in the case of embryonic stem cells. Furthermore, since iPSCs are developed from patient’s own cells, the body won’t typically develop a severe immune response against them. Today, besides creating therapies for incurable diseases, the pharmaceutical industry tends to adopt iPSCs for screening purposes that will dramatically decrease the cost of clinical trials.

The Increasing Potential of Virtual Reality in Drug Design

   1180
The Increasing Potential of Virtual Reality in Drug Design

Using virtual reality (VR) for manipulating 3D models of molecules in the context of drug design is an emerging technological opportunity, which increasingly grabs attention among scientists at biotech startups, and larger pharmaceutical organizations. 

Microbiome: Can Human Microbes Become A Panacea?

   899
Microbiome: Can Human Microbes Become A Panacea?

The microbiome is implicated in a number of metabolic pathways and communicates closely with our body in health and diseases. Imbalance of microflora is linked to obesity, diabetes, allergies, cancer, and even depression and autism. However, these facts have been ignored for decades. But today, the microbiome market is catching up, attracting considerable investments. The Wall Street Journal reported in 2018 that “from 2011 through 2015, venture funding in microbiome firms soared 458.5 percent to $114.5 million, while overall venture investment grew 103.4 percent to $75.29 billion. 

Top Companies At The Forefront Of RNA Therapeutics Development

   7551
Top Companies At The Forefront Of RNA Therapeutics Development

Alongside the topic of gene editing technologies that keeps making headlines these days, there is also a wave of breakthroughs in the field of RNA-targeting medicines, primarily falling into the following two categories: antisense oligonucleotides (ASO), and RNA interference (RNAi) technologies. (another promising approach, dealing with editing RNA itself by ADAR enzymes, is not covered in this post). 

A Race For Better Gene Editing Tech Is On

   1995
A Race For Better Gene Editing Tech Is On

A transformative technology for gene editing - clustered regularly interspaced short palindromic repeats (CRISPR) -- has become ubiquitous, at least in research laboratories, where scientists efficiently adopted CRISPR technology to manipulate genes of interest. Still, applying it for humans is associated with greater risks and faces ethical issues. However, alongside a too reckless experiment of a Chinese scientist who edited babies’ genomes, plenty of companies have made well-thought progress toward transferring gene editing technologies into the clinic. Here we make a brief but pithy review on up-to-date gene editing approaches and start-up companies active in this area.

A Market Review Of DNA-encoded Libraries Technology In Drug Discovery

   6475
A Market Review Of DNA-encoded Libraries Technology In Drug Discovery

The interest of pharma organizations in DNA-encoded chemical libraries (DEL) technology has been growing over the years, with numerous pharma organizations now having their own screening programs using DELs, or outsourcing capabilities from specialized DEL providers.

This report provides a bird's view on the DEL market, including a brief summary of DEL technology benefits and limitations, key players, major research deals, and several examples of successful hit discovery programs using DELs.